These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 9207232)

  • 1. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth.
    Laterra J; Rosen E; Nam M; Ranganathan S; Fielding K; Johnston P
    Biochem Biophys Res Commun; 1997 Jun; 235(3):743-7. PubMed ID: 9207232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of TRPM channels in glioma.
    Chen Z; Xie H; Liu J; Zhao J; Huang R; Xiang Y; Wu H; Tian D; Bian E; Xiong Z
    Cancer Biol Ther; 2024 Dec; 25(1):2338955. PubMed ID: 38680092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very long-chain acyl-CoA synthetase 3 mediates onco-sphingolipid metabolism in malignant glioma.
    Kolar EA; Shi X; Clay EM; Moser AB; Lal B; Nirujogi RS; Pandey A; Bandaru VVR; Laterra J; Pei Z; Watkins PA
    Med Res Arch; 2021 May; 9(5):. PubMed ID: 34395855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRP Channels in Brain Tumors.
    Chinigò G; Castel H; Chever O; Gkika D
    Front Cell Dev Biol; 2021; 9():617801. PubMed ID: 33928077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HGF/MET Signaling in Malignant Brain Tumors.
    Mulcahy EQX; Colόn RR; Abounader R
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
    Affronti ML; Jackman JG; McSherry F; Herndon JE; Massey EC; Lipp E; Desjardins A; Friedman HS; Vlahovic G; Vredenburgh J; Peters KB
    Oncologist; 2018 Aug; 23(8):889-e98. PubMed ID: 29666296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multiple paths towards MET receptor addiction in cancer.
    Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
    Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib Loaded DSPE-PEG
    Yang Q; Moulder K R; Cohen MS; Cai S; Forrest LM
    BAOJ Pharm Sci; 2015 Jan; 1():. PubMed ID: 25688382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.
    Liang QL; Mo ZY; Wang P; Li X; Liu ZX; Zhou ZM
    Med Oncol; 2014 Sep; 31(9):122. PubMed ID: 25064731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification.
    Camacho CV; Todorova PK; Hardebeck MC; Tomimatsu N; Gil del Alcazar CR; Ilcheva M; Mukherjee B; McEllin B; Vemireddy V; Hatanpaa K; Story MD; Habib AA; Murty VV; Bachoo R; Burma S
    Oncogene; 2015 Feb; 34(8):1064-72. PubMed ID: 24632607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
    Hagemann C; Fuchs S; Monoranu CM; Herrmann P; Smith J; Hohmann T; Grabiec U; Kessler AF; Dehghani F; Löhr M; Ernestus RI; Vince GH; Stein U
    Neuro Oncol; 2013 Dec; 15(12):1696-709. PubMed ID: 24220141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of semaphorins and their receptors in gliomas.
    Law JW; Lee AY
    J Signal Transduct; 2012; 2012():902854. PubMed ID: 23050142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro.
    Guo YF; Wang XB; Tian XY; Li Y; Li B; Huang Q; Zhang M; Li Z
    World J Surg Oncol; 2012 Jun; 10():128. PubMed ID: 22741575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular profile of microglia under the influence of glioma.
    Li W; Graeber MB
    Neuro Oncol; 2012 Aug; 14(8):958-78. PubMed ID: 22573310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype.
    Li Y; Li A; Glas M; Lal B; Ying M; Sang Y; Xia S; Trageser D; Guerrero-Cázares H; Eberhart CG; Quiñones-Hinojosa A; Scheffler B; Laterra J
    Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9951-6. PubMed ID: 21628563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
    Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
    Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.
    Zhang Y; Guessous F; Kofman A; Schiff D; Abounader R
    IDrugs; 2010 Feb; 13(2):112-21. PubMed ID: 20127563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
    Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
    Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity.
    Pei Z; Sun P; Huang P; Lal B; Laterra J; Watkins PA
    Cancer Res; 2009 Dec; 69(24):9175-82. PubMed ID: 19920185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.